Procter & Gamble Health Limited (PGHL.NS)
INR 5103.0
(-0.02%)
INR 5103.0
(-0.02%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.99 Billion INR | -47.63% |
| 2022 | 5.71 Billion INR | 33.42% |
| 2021 | 4.28 Billion INR | -0.68% |
| 2020 | 4.31 Billion INR | 110.62% |
| 2019 | 2.04 Billion INR | -48.75% |
| 2018 | 3.99 Billion INR | -15.39% |
| 2017 | 4.72 Billion INR | 4.66% |
| 2016 | 4.51 Billion INR | 7.18% |
| 2015 | 4.21 Billion INR | 5.36% |
| 2014 | 3.99 Billion INR | 15.77% |
| 2013 | 3.45 Billion INR | 46.23% |
| 2012 | 2.36 Billion INR | 7.77% |
| 2011 | 2.19 Billion INR | 6.69% |
| 2010 | 2.05 Billion INR | 20.46% |
| 2009 | 1.7 Billion INR | 23.83% |
| 2008 | 1.37 Billion INR | 55.67% |
| 2007 | 884.7 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 651 Million INR | -39.63% |
| 2023 Q3 | 627.2 Million INR | 3.67% |
| 2023 FY | 2.99 Billion INR | -47.63% |
| 2023 Q2 | 605 Million INR | -55.39% |
| 2023 Q1 | 1.35 Billion INR | -19.56% |
| 2023 Q4 | 1.07 Billion INR | 71.92% |
| 2022 Q1 | 1.27 Billion INR | 141.35% |
| 2022 Q2 | 1.26 Billion INR | -1.03% |
| 2022 Q3 | 1.49 Billion INR | 18.05% |
| 2022 Q4 | 1.68 Billion INR | 12.98% |
| 2022 FY | 5.71 Billion INR | 33.42% |
| 2021 Q1 | 1.19 Billion INR | 9.99% |
| 2021 Q3 | 1.24 Billion INR | -6.02% |
| 2021 Q4 | 529.2 Million INR | -57.44% |
| 2021 Q2 | 1.32 Billion INR | 11.09% |
| 2021 FY | 4.28 Billion INR | -0.68% |
| 2020 Q3 | 1.29 Billion INR | 35.06% |
| 2020 Q2 | 957.4 Million INR | -2.57% |
| 2020 FY | 4.31 Billion INR | 110.62% |
| 2020 Q1 | 982.7 Million INR | -6.17% |
| 2020 Q4 | 1.08 Billion INR | -16.26% |
| 2019 Q4 | 1.04 Billion INR | 12.1% |
| 2019 FY | 2.04 Billion INR | -48.75% |
| 2019 Q3 | 934.21 Million INR | -11.66% |
| 2019 Q2 | 1.05 Billion INR | 4.33% |
| 2019 Q1 | 1.01 Billion INR | -16.94% |
| 2018 Q4 | 1.22 Billion INR | 16.12% |
| 2018 Q2 | 1.27 Billion INR | 24.89% |
| 2018 Q1 | 1.01 Billion INR | -4.07% |
| 2018 FY | 3.99 Billion INR | -15.39% |
| 2018 Q3 | 1.05 Billion INR | -17.36% |
| 2017 Q3 | 1.51 Billion INR | 2.55% |
| 2017 FY | 4.72 Billion INR | 4.66% |
| 2017 Q4 | 1.06 Billion INR | -29.94% |
| 2017 Q2 | 1.47 Billion INR | 11.15% |
| 2017 Q1 | 1.32 Billion INR | 1.18% |
| 2016 Q3 | 1.21 Billion INR | -6.2% |
| 2016 Q4 | 1.31 Billion INR | 8.3% |
| 2016 FY | 4.51 Billion INR | 7.18% |
| 2016 Q1 | 1.09 Billion INR | -2.54% |
| 2016 Q2 | 1.29 Billion INR | 17.79% |
| 2015 Q2 | 1.06 Billion INR | -4.66% |
| 2015 FY | 4.21 Billion INR | 5.36% |
| 2015 Q4 | 1.12 Billion INR | 0.45% |
| 2015 Q3 | 1.12 Billion INR | 5.2% |
| 2015 Q1 | 1.11 Billion INR | 12.61% |
| 2014 Q4 | 993.03 Million INR | 4.19% |
| 2014 FY | 3.99 Billion INR | 15.77% |
| 2014 Q1 | 962.04 Million INR | 9.47% |
| 2014 Q2 | 1.15 Billion INR | 20.25% |
| 2014 Q3 | 953.09 Million INR | -17.61% |
| 2013 Q4 | 878.85 Million INR | -12.19% |
| 2013 FY | 3.45 Billion INR | 46.23% |
| 2013 Q2 | 848.64 Million INR | -3.58% |
| 2013 Q1 | 880.12 Million INR | -2.77% |
| 2013 Q3 | 1 Billion INR | 17.94% |
| 2012 Q4 | 905.17 Million INR | 10.38% |
| 2012 Q3 | 820.05 Million INR | 110.1% |
| 2012 FY | 2.36 Billion INR | 7.77% |
| 2012 Q2 | 390.31 Million INR | -39.99% |
| 2012 Q1 | 650.36 Million INR | -0.96% |
| 2011 Q4 | 656.69 Million INR | 14.46% |
| 2011 Q1 | 644.56 Million INR | 0.0% |
| 2011 Q2 | 340.47 Million INR | -47.18% |
| 2011 Q3 | 573.71 Million INR | 68.5% |
| 2011 FY | 2.19 Billion INR | 6.69% |
| 2010 FY | 2.05 Billion INR | 20.46% |
| 2009 FY | 1.7 Billion INR | 23.83% |
| 2008 FY | 1.37 Billion INR | 55.67% |
| 2007 FY | 884.7 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Gufic Biosciences Limited | 1.18 Billion INR | -152.438% |
| IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | -36.093% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 79.276% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -626.286% |
| Mangalam Drugs & Organics Limited | 162.22 Million INR | -1746.414% |
| Sigachi Industries Limited | 579.88 Million INR | -416.549% |
| Solara Active Pharma Sciences Limited | 2.55 Billion INR | -17.278% |
| Vaishali Pharma Limited | 84.02 Million INR | -3464.722% |
| Venus Remedies Limited | 1.91 Billion INR | -56.313% |
| Morepen Laboratories Limited | 1.98 Billion INR | -50.716% |
| Innova Captab Limited | 931.03 Million INR | -221.73% |
| Brooks Laboratories Limited | 51.18 Million INR | -5752.677% |
| Eris Lifesciences Limited | 4.94 Billion INR | 39.4% |
| Ind-Swift Limited | 946.56 Million INR | -216.449% |
| Orchid Pharma Limited | 800.77 Million INR | -274.064% |
| Alkem Laboratories Limited | 32.83 Billion INR | 90.877% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 74.268% |
| Aarti Drugs Limited | 1.16 Billion INR | -156.57% |
| Albert David Limited | 1.02 Billion INR | -191.907% |
| Alembic Limited | 872.45 Million INR | -243.329% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 81.125% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -41.014% |
| Bafna Pharmaceuticals Limited | 455.58 Million INR | -557.484% |
| Bajaj HealthCare Limited | 985.34 Million INR | -203.995% |
| Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -43820.821% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -178.853% |
| FDC Limited | 3.49 Billion INR | 14.411% |
| Hester Biosciences Limited | 908.84 Million INR | -229.585% |
| Hikal Limited | 4.46 Billion INR | 32.896% |
| Ipca Laboratories Limited | 18.98 Billion INR | 84.224% |
| Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | -583.024% |
| Laurus Labs Limited | 11.9 Billion INR | 74.849% |
| Medico Remedies Limited | 59.67 Million INR | -4919.522% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 98.057% |
| Nectar Lifesciences Limited | 932.7 Million INR | -221.154% |
| RPG Life Sciences Limited | 1.63 Billion INR | -83.149% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -113.532% |
| Themis Medicare Limited | 1.12 Billion INR | -166.069% |
| Unichem Laboratories Limited | 6.72 Billion INR | 55.464% |
| Wanbury Limited | 978.96 Million INR | -205.976% |
| Windlas Biotech Limited | 1 Billion INR | -197.603% |
| ZIM Laboratories Limited | 1.01 Billion INR | -195.679% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 2.57% |
| Lupin Limited | 125.09 Billion INR | 97.606% |
| Sakar Healthcare Limited | 204.07 Million INR | -1367.765% |
| Aurobindo Pharma Limited | 55.65 Billion INR | 94.618% |
| Divi's Laboratories Limited | 14.17 Billion INR | 78.861% |
| AstraZeneca Pharma India Limited | 2.47 Billion INR | -21.1% |
| Mankind Pharma Limited | 29.27 Billion INR | 89.767% |
| Sequent Scientific Limited | 2.9 Billion INR | -3.225% |
| Neuland Laboratories Limited | 2.92 Billion INR | -2.241% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 79.751% |
| Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 93.62% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 97.608% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | -43.044% |
| Wockhardt Limited | 8.48 Billion INR | 64.677% |
| Bal Pharma Limited | 555.62 Million INR | -439.104% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 96.876% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -111.059% |
| Par Drugs and Chemicals Limited | 58.28 Million INR | -5038.963% |
| Caplin Point Laboratories Limited | 2.17 Billion INR | -37.751% |
| Shilpa Medicare Limited | 3.33 Billion INR | 10.161% |
| Valiant Laboratories Limited | 138.02 Million INR | -2070.124% |
| Ajanta Pharma Limited | 30.46 Billion INR | 90.167% |
| Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -20975.072% |
| Granules India Limited | 10.31 Billion INR | 70.955% |
| Medicamen Biotech Limited | 335.16 Million INR | -793.704% |
| Syncom Formulations (India) Limited | 345.63 Million INR | -766.642% |
| Piramal Enterprises Limited | 63.65 Billion INR | 95.294% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 86.017% |
| NATCO Pharma Limited | 10.05 Billion INR | 70.219% |
| Suven Life Sciences Limited | 109.75 Million INR | -2629.294% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -6389.73% |
| Strides Pharma Science Limited | 9.16 Billion INR | 67.307% |
| Indoco Remedies Limited | 12.06 Billion INR | 75.165% |
| Alpa Laboratories Limited | 127.38 Million INR | -2251.547% |
| Lasa Supergenerics Limited | 291.17 Million INR | -928.732% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 2.646% |